Tianjin Tasly Pharma signed a $24 million licensing agreement to acquire greater China rights for a kidney disease treatment being developed by Japan’s EA Pharmaceutical. AJT-240 is aimed at a calcium disorder that occurs as a complication of end-stage renal impairment and hemodialysis. EA Pharma is currently conducting a Phase II trial of AJT-240 in Japan. Tasly will have the rights to develop, produce and commercialize the drug in China.
Source: China Biotoday
